Search

Your search keyword '"Caggese L"' showing total 63 results

Search Constraints

Start Over You searched for: Author "Caggese L" Remove constraint Author: "Caggese L"
63 results on '"Caggese L"'

Search Results

2. Chorea in patients with AIDS

3. Chorea in patients with AIDS

4. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

5. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

6. European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis: Report from Italy

7. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts

8. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

9. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

10. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

11. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

12. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures

13. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients

14. Genetic polymorphisms differently influencing the emergence of atrophy and fataccumulation in HIV-related lipodystrophy

15. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

16. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

17. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

18. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis

19. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

20. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) study

21. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads

22. Economic evaluation of HIV treatments: The I.CO.N.A. cohort study

23. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

25. Lo studio di coorte I.CO.N.A. (Italian CohOrt Naive Antiretrovirals): caratteristiche all’arruolamento dei primi 1676 soggetti

26. HIV-Related Thrombocytopenia: Four Different Clinical Subsets

27. Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia

28. Chorea in patients with AIDS

29. Short-term adverse effects from and discontiuation of antiretroviral post-exposure prophylaxis

30. Pneumothorax in AIDS patients

32. Evolution of HVR-1 Quasispecies after 1-Year Treatment in HIV/HCV-Coinfected Patients According to the Pattern of Response to Highly Active Antiretroviral Therapy

33. Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals

34. The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?

35. Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems

36. Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy

37. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

40. Drug-resistant tuberculosis in human immunodeficiency virus infected persons in Italy

41. Prophylactic and therapeutic guidelines for yeast mucosal infections in HIV-infected individuals

42. HIV-related non Hodgkin's lymphomas (NHL): report of 53 cases

43. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

44. Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis.

45. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

46. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy.

47. Anaplastic large cell (CD30/Ki-1+) lymphoma in HIV+ patients: clinical and pathological findings in a group of ten patients.

48. Thrombotic thrombocytopenic purpura associated with HIV infection: report of two cases.

49. [An observational study on 8 years of admissions for HIV-related pathology at an infectious disease center].

50. Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia.

Catalog

Books, media, physical & digital resources